tralokinumab   Click here for help

GtoPdb Ligand ID: 8001

Synonyms: Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm
Approved drug Immunopharmacology Ligand
tralokinumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
1. Adams B. 
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease.
Accessed on 09/02/2018. Modified on 09/02/2018.,
2. Thom G, Minter R. (2012)
Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display.
Methods Mol Biol, 805: 393-401. [PMID:22094818]
3. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. (1998)
Interleukin-13: central mediator of allergic asthma.
Science, 282 (5397): 2258-61. [PMID:9856949]
4. Wynn TA. (2003)
IL-13 effector functions.
Annu Rev Immunol, 21: 425-56. [PMID:12615888]